Document Detail

Over-the-counter β2-agonist purchase versus script: a cross-sectional study.
MedLine Citation:
PMID:  22040532     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Purchase of short-acting β(2)-agonist (SABA), but not anti-inflammatory asthma medication, is permitted in Australia without a doctor's prescription. This has been associated with worse asthma outcomes. We sought to compare the asthma outcomes between those purchasing SABA with and without a doctor's prescription.
DESIGN: Cross-sectional study, using stratified randomisation of pharmacies.
SETTING: 43 pharmacies in Victoria, Australia.
PARTICIPANTS: Up to 10 consecutive adults purchasing β(2)-agonists were recruited from each pharmacy, with 316 adults in total.
OUTCOME MEASURES: Participants underwent spirometry and questionnaires on respiratory health, asthma control, Quality of Life and medication adherence. Asthma severity was determined by GINA medication step. Regression analyses were performed that allowed for clustering by pharmacy.
RESULTS: Of 316 individuals recruited (65% participation rate), 191 (60%) purchased a β(2)-agonist with a prescription. Purchase of SABA without prescription was not associated with worse asthma outcomes or lung function. Mean (±SD) asthma control score (ACQ) was 1.65 ± 1.03; only 63 (20%) had well-controlled asthma (ACQ < 0.75). Anti-inflammatory asthma medication was owned by 188 (60%) of participants, of whom 157 (83%) reported using this in the last 7 days. There was no correlation between medication adherence scores and asthma control. Forty-seven participants (15%) had an FEV(1) below 80% predicted and did not own an anti-inflammatory asthma medication.
CONCLUSION: Purchase of SABA without prescription was not associated with worse asthma outcomes in Australia. Although many patients reported symptoms of asthma, this did not appear to be associated with reported adherence to anti-inflammatory asthma medication.
Jo A Douglass; Dianne P Goeman; Edwina A McCarthy; Susan M Sawyer; Rosalie A Aroni; Kay Stewart; Michael J Abramson
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2011-10-29
Journal Detail:
Title:  Respiratory medicine     Volume:  106     ISSN:  1532-3064     ISO Abbreviation:  Respir Med     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2011-12-26     Completed Date:  2012-02-24     Revised Date:  2014-07-30    
Medline Journal Info:
Nlm Unique ID:  8908438     Medline TA:  Respir Med     Country:  England    
Other Details:
Languages:  eng     Pagination:  223-9     Citation Subset:  IM    
Copyright Information:
Copyright © 2011 Elsevier Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Agonists / therapeutic use*
Anti-Inflammatory Agents / therapeutic use*
Asthma / drug therapy*,  epidemiology,  physiopathology
Cross-Sectional Studies
Medication Adherence / statistics & numerical data
Middle Aged
Nonprescription Drugs*
Patient Acceptance of Health Care / statistics & numerical data
Prescription Drugs*
Severity of Illness Index
Treatment Outcome
Victoria / epidemiology
Reg. No./Substance:
0/Adrenergic beta-Agonists; 0/Anti-Inflammatory Agents; 0/Nonprescription Drugs; 0/Prescription Drugs

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Does ampicillin-sulbactam cause false positivity of (1,3)-beta-D-glucan assay? A prospective evaluat...
Next Document:  Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD.